Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study

Area of Science:

• Neuroimaging
• Psychiatry
• Neuropharmacology

Background:

• Metabotropic glutamate receptor 5 (mGluR5) is implicated in major depressive disorder (MDD) pathophysiology.
• Previous studies suggest a role for mGluR5 in MDD, but in vivo evidence is limited.
• Glutamatergic system dysregulation is increasingly recognized in MDD.

Purpose of the Study:

• To investigate the in vivo role of mGluR5 availability in MDD using positron emission tomography (PET).
• To examine the relationship between glutamate levels and mGluR5 availability in individuals with MDD.
• To compare mGluR5 availability and glutamate levels between MDD patients and healthy controls (HC).

Main Methods:

• Sixty-five participants (30 MDD, 35 HC) underwent [18F]FPEB PET scans to measure mGluR5 volume of distribution (VT) and distribution volume ratio (DVR).
• A subgroup (16 MDD, 23 HC) completed proton magnetic resonance spectroscopy (1H MRS) to assess anterior cingulate cortex (ACC) glutamate, glutamine, and Glx levels.
• Correlation analyses were performed between mGluR5 DVR and glutamate/Glx levels.

Main Results:

• No significant differences in mGluR5 VT were found between MDD patients and HC.
• Individuals with MDD exhibited elevated ACC glutamate, glutamine, and Glx levels compared to HC.
• A significant negative correlation was observed between ACC mGluR5 DVR and glutamate/Cr and Glx/Cr levels in the MDD group.

Conclusions:

• This study reveals an inverse relationship between in vivo mGluR5 availability and glutamate levels in MDD.
• The findings underscore the importance of the glutamatergic system in the neurobiology of depression.
• Further research is warranted to explore the therapeutic potential of targeting the glutamatergic system in MDD.